---
document_datetime: 2026-01-19 16:46:06
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/wegovy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: wegovy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.4191361
conversion_datetime: 2026-01-20 20:18:23.593273
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Wegovy

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 23/10/2025                          |                                             |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000257476                     | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on 'Gastroparesis' based on data from clinical trials. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update section 6.6 of the SmPC.                                                                                                                                |            |             |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Variation type IB / EMA/VR/0000287437 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. - - Accepted C.I.z - to update sections 4.4 and 4.8 of the SmPC and sections 2 and 4 of the Package Leaflet to include the warning for Non- Arteritic Anterior Ischemic Optic Neuropathy (NAION) in line with the outcome of the Pharmacovigilance Risk Assessment Committee (PRAC) Assessment Report for the Post-Authorisation Measure Procedures EMA/PAM/0000262449, EMA/ PAM/0000262475, and EMA/PAM/0000262468 of PSUR | 25/09/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|                                       | EMEA/H/C/PSUSA/00010671/202405 (1 June 2023 - 31 May 2024).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000275558 | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.z Other changes - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.g.5 Implementation of changes foreseen in an approved change management protocol - B.II.g.5.c Implementation of a change for a biological/immunological | 17/06/2025 | N/A |
| Variation type IB / EMA/VR/0000244317 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.3 Change in the manufacturing process of the finished product, including an                                                                                                                                                                                                                                                                                                                                                                  | 10/04/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | intermediate used in the manufacture of the finished product - B.II.b.3.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000246575 | This was an application for a group of variations. B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including batch control/testing - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.z Other changes - Accepted | 19/02/2025 | N/A |